Alnylam Provides Pipeline Update, Completes Phase I Trial of Liver Cancer Drug | GenomeWeb

By Doug Macron

Alnylam Pharmaceuticals this week provided an update on its drug-development pipeline, noting that it remains on track to report phase I data from two programs and unveil two additional clinical candidates before year's end.

The company also reported its second-quarter financial results and disclosed that it has finished a phase I study of the systemically delivered liver cancer treatment ALN-VSP, formerly ALN-VSP02.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.